Obermatt
See Similar Stocks →

Rhythm Pharmaceuticals

NMQ:RYTM · US76243J1051
BiotechnologyMedium

360

31
Profit price81
Owner Earnings Yield1
Dividend Yield1
Price/Sales17
EV / Gross Profit18
Price/Book97
Return on Capital18
Cash Return on Capital8
Return on Equity10
EBIT Margin12
Gross Profitability81
Accruals49
Owner Earnings Margin36
Sales growth91
Profit growth9
Reinvestment34
Price momentum46
Debt load41
Refinancing50
Debt Payback1
Liquidity31
Analyst ratings59
Opinion Changes50
Price Target Upside64
Market mood83
Value Creation17/20strong value creator
  • Creates more value than its capital costs
  • Owner earnings growing
  • Owner earnings per share growing
  • Reinvests at strong returns
  • Solid earnings base

What this means

Rhythm Pharmaceuticals generates returns well above its cost of capital, the foundation of durable shareholder value.

Based on 3/5 components.

Profile

CountryUSA
IndustryBiotechnology
SizeMedium
TypePublic Company
ExchangeNASDAQGM
Founded2013
Employees386
Websiterhythmtx.com
ISINUS76243J1051
Last UpdateApr 2, 2026
Indices
NASDAQ (USA)
Themes
ObesityEndocrinologyGenetic DisorderGeneticsBiotechnologyPharmaceuticalTherapeutics

Description

Rhythm Pharmaceuticals, Inc. (Rhythm) operates as a global, commercial-stage biopharmaceutical company dedicated to transforming the lives of patients living with rare neuroendocrine diseases. The company is focused on advancing melanocortin-4 recep…

Analysis

Middle-of-the-road

Rhythm Pharmaceuticals, Inc. sits in the middle of our grid: average quality, average price, no obvious signal in either direction.

Valuation data is not available for this company.

Growth is moderate; the safety picture is adequate. The company scores 17/20 on our value-creation score: strong value creator.

No flags apply to this company at this time: accounts, balance sheet, and cash quality all pass. A clean bill of health is meaningful, not just the absence of a warning. This analysis describes numbers; it is not investment advice.

360° rank · history

1007550250
91
2026

All-time high

92

Mar 2026

All-time low

91

Jun 2026

Average rank

92

across all years

Detailed & Historical Ranks

Deep dive into 15 detailed ranks and 3 years of history.

Current202520242023
Price/Sales
17
—
—
—
Price/Earnings
90
—
—
—
Price/Book
97
—
—
—
Dividend Yield
1
—
—
—
Value (overall)
90
—
—
—

Cells are coloured by rank band (red weak → green strong). Sentiment & 360° history begins 2023.

Similar Stocks

The companies this stock is ranked against.

Compare Rhythm Pharmaceuticals with its peers
Verrica Pharmaceuticals
NAQ:VRCA
55
CountryUSA
IndustryPharmaceuticals
SizeSmall
Full Stock Analysis →
Kura Oncology
NSQ:KURA
30
CountryUSA
IndustryBiotechnology
SizeSmall
Full Stock Analysis →
Contineum Therapeutics
NSQ:CTNM
80
CountryUSA
IndustryPharmaceuticals
SizeSmall
Full Stock Analysis →
Cardiol Therapeutics
TOR:CRDL
81
CountryCanada
IndustryPharmaceuticals
SizeX-Small
Full Stock Analysis →
Rezolute
NAQ:RZLT
53
CountryUSA
IndustryBiotechnology
SizeSmall
Full Stock Analysis →
Tarsus Pharmaceuticals
NSQ:TARS
29
CountryUSA
IndustryPharmaceuticals
SizeMedium
Full Stock Analysis →

Make Sense of the Ranks

Every rank runs 1–100 against true peers. Higher is always better.

360° View
1 · Watch OutGood· 100
Value
1 · ExpensiveGood Value· 100
Quality
1 · Weak FundamentalsHigh Quality· 100
Growth
1 · Tough TimesHigh Growth· 100
Safety
1 · High LeverageWell-Financed· 100
Sentiment
1 · SkepticismPositive· 100
Learn More →